Your browser doesn't support javascript.
loading
Systematic identification of engineered methionines and oxaziridines for efficient, stable, and site-specific antibody bioconjugation.
Elledge, Susanna K; Tran, Hai L; Christian, Alec H; Steri, Veronica; Hann, Byron; Toste, F Dean; Chang, Christopher J; Wells, James A.
Afiliação
  • Elledge SK; Department of Pharmaceutical Chemistry, University of California, San Francisco, CA 94158.
  • Tran HL; Department of Pharmaceutical Chemistry, University of California, San Francisco, CA 94158.
  • Christian AH; Department of Chemistry, University of California, Berkeley, CA 94720.
  • Steri V; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94158.
  • Hann B; Preclinical Therapeutics Core, University of California, San Francisco, CA 94158.
  • Toste FD; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94158.
  • Chang CJ; Preclinical Therapeutics Core, University of California, San Francisco, CA 94158.
  • Wells JA; Department of Chemistry, University of California, Berkeley, CA 94720.
Proc Natl Acad Sci U S A ; 117(11): 5733-5740, 2020 03 17.
Article em En | MEDLINE | ID: mdl-32123103
ABSTRACT
The field of chemical modification of proteins has been dominated by random modification of lysines or more site-specific labeling of cysteines, each with attendant challenges. Recently, we have developed oxaziridine chemistry for highly selective modification of methionine called redox-activated chemical tagging (ReACT) but have not broadly tested the molecular parameters for efficient and stable protein modification. Here we systematically scanned methionines throughout one of the most popular antibody scaffolds, trastuzumab, used for antibody engineering and drug conjugation. We tested the expression, reactivities, and stabilities of 123 single engineered methionines distributed over the surface of the antibody when reacted with oxaziridine. We found uniformly high expression for these mutants and excellent reaction efficiencies with a panel of oxaziridines. Remarkably, the stability to hydrolysis of the sulfimide varied more than 10-fold depending on temperature and the site of the engineered methionine. Interestingly, the most stable and reactive sites were those that were partially buried, presumably because of their reduced access to water. There was also a 10-fold variation in stability depending on the nature of the oxaziridine, which was determined to be inversely correlated with the electrophilic nature of the sulfimide. Importantly, the stabilities of the best analogs were sufficient to support their use as antibody drug conjugates and potent in a breast cancer mouse xenograft model over a month. These studies provide key parameters for broad application of ReACT for efficient, stable, and site-specific antibody and protein bioconjugation to native or engineered methionines.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Aziridinas / Imunoconjugados / Metionina Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Aziridinas / Imunoconjugados / Metionina Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article